Cargando…
Epigenetics in diabetic nephropathy, immunity and metabolism
When it comes to the epigenome, there is a fine line between clarity and confusion—walk that line and you will discover another fascinating level of transcription control. With the genetic code representing the cornerstone of rules for information that is encoded to proteins somewhere above the geno...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448927/ https://www.ncbi.nlm.nih.gov/pubmed/29128937 http://dx.doi.org/10.1007/s00125-017-4490-1 |
_version_ | 1783408757992062976 |
---|---|
author | Keating, Samuel T. van Diepen, Janna A. Riksen, Niels P. El-Osta, Assam |
author_facet | Keating, Samuel T. van Diepen, Janna A. Riksen, Niels P. El-Osta, Assam |
author_sort | Keating, Samuel T. |
collection | PubMed |
description | When it comes to the epigenome, there is a fine line between clarity and confusion—walk that line and you will discover another fascinating level of transcription control. With the genetic code representing the cornerstone of rules for information that is encoded to proteins somewhere above the genome level there is a set of rules by which chemical information is also read. These epigenetic modifications show a different side of the genetic code that is diverse and regulated, hence modifying genetic transcription transiently, ranging from short- to long-term alterations. While this complexity brings exquisite control it also poses a formidable challenge to efforts to decode mechanisms underlying complex disease. Recent technological and computational advances have improved unbiased acquisition of epigenomic patterns to improve our understanding of the complex chromatin landscape. Key to resolving distinct chromatin signatures of diabetic complications is the identification of the true physiological targets of regulatory proteins, such as reader proteins that recognise, writer proteins that deposit and eraser proteins that remove specific chemical moieties. But how might a diverse group of proteins regulate the diabetic landscape from an epigenomic perspective? Drawing from an ever-expanding compendium of experimental and clinical studies, this review details the current state-of-play and provides a perspective of chromatin-dependent mechanisms implicated in diabetic complications, with a special focus on diabetic nephropathy. We hypothesise a codified signature of the diabetic epigenome and provide examples of prime candidates for chemical modification. As for the pharmacological control of epigenetic marks, we explore future strategies to expedite and refine the search for clinically relevant discoveries. We also consider the challenges associated with therapeutic strategies targeting epigenetic pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-017-4490-1) contains a slideset of the figures for download, which is available to authorised users. |
format | Online Article Text |
id | pubmed-6448927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-64489272019-04-17 Epigenetics in diabetic nephropathy, immunity and metabolism Keating, Samuel T. van Diepen, Janna A. Riksen, Niels P. El-Osta, Assam Diabetologia Review When it comes to the epigenome, there is a fine line between clarity and confusion—walk that line and you will discover another fascinating level of transcription control. With the genetic code representing the cornerstone of rules for information that is encoded to proteins somewhere above the genome level there is a set of rules by which chemical information is also read. These epigenetic modifications show a different side of the genetic code that is diverse and regulated, hence modifying genetic transcription transiently, ranging from short- to long-term alterations. While this complexity brings exquisite control it also poses a formidable challenge to efforts to decode mechanisms underlying complex disease. Recent technological and computational advances have improved unbiased acquisition of epigenomic patterns to improve our understanding of the complex chromatin landscape. Key to resolving distinct chromatin signatures of diabetic complications is the identification of the true physiological targets of regulatory proteins, such as reader proteins that recognise, writer proteins that deposit and eraser proteins that remove specific chemical moieties. But how might a diverse group of proteins regulate the diabetic landscape from an epigenomic perspective? Drawing from an ever-expanding compendium of experimental and clinical studies, this review details the current state-of-play and provides a perspective of chromatin-dependent mechanisms implicated in diabetic complications, with a special focus on diabetic nephropathy. We hypothesise a codified signature of the diabetic epigenome and provide examples of prime candidates for chemical modification. As for the pharmacological control of epigenetic marks, we explore future strategies to expedite and refine the search for clinically relevant discoveries. We also consider the challenges associated with therapeutic strategies targeting epigenetic pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-017-4490-1) contains a slideset of the figures for download, which is available to authorised users. Springer Berlin Heidelberg 2017-11-11 2018 /pmc/articles/PMC6448927/ /pubmed/29128937 http://dx.doi.org/10.1007/s00125-017-4490-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Keating, Samuel T. van Diepen, Janna A. Riksen, Niels P. El-Osta, Assam Epigenetics in diabetic nephropathy, immunity and metabolism |
title | Epigenetics in diabetic nephropathy, immunity and metabolism |
title_full | Epigenetics in diabetic nephropathy, immunity and metabolism |
title_fullStr | Epigenetics in diabetic nephropathy, immunity and metabolism |
title_full_unstemmed | Epigenetics in diabetic nephropathy, immunity and metabolism |
title_short | Epigenetics in diabetic nephropathy, immunity and metabolism |
title_sort | epigenetics in diabetic nephropathy, immunity and metabolism |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448927/ https://www.ncbi.nlm.nih.gov/pubmed/29128937 http://dx.doi.org/10.1007/s00125-017-4490-1 |
work_keys_str_mv | AT keatingsamuelt epigeneticsindiabeticnephropathyimmunityandmetabolism AT vandiepenjannaa epigeneticsindiabeticnephropathyimmunityandmetabolism AT riksennielsp epigeneticsindiabeticnephropathyimmunityandmetabolism AT elostaassam epigeneticsindiabeticnephropathyimmunityandmetabolism |